Healthpeak Properties stock: UBS raises target to USD 22

Published on 11/12/2026 at 02:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Healthpeak Properties stock remains under a neutral UBS view. The revised target gives investors a fresh reference for valuation.

Analyst target moves higher

UBS raised its Healthpeak price target while retaining a neutral rating.
The revision gives investors a fresh reference point for valuing the healthcare real estate investment trust.
Healthpeak focuses on properties used for medical research and healthcare services.

DOC, US42250P1030, Illustration mit AI erstellt.

UBS raised its price target for Healthpeak Properties to USD 22 from USD 20 while keeping a neutral rating, according to MarketScreener. The analyst revision was published on Wednesday, November 11, 2026.

Healthpeak Properties stock traded at 18.42 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 11. The quote provides the latest overnight reference for investors following the analyst change.

Neutral view remains in place

UBS's unchanged neutral stance tempers the effect of the higher target. The revision signals a more constructive valuation reference without amounting to a bullish recommendation.

Healthpeak is a fully integrated healthcare real estate investment trust. Its portfolio activity covers the acquisition, management and development of properties used for medical research and the delivery of healthcare services.

Healthcare real estate platform

Healthpeak operates from the United States and focuses on healthcare facilities. In the healthcare real estate market, it competes with specialized owners such as Welltower, Ventas and Healthcare Realty Trust. Healthpeak's profile is centered on medical research and healthcare delivery properties, while those peers provide broader or differently concentrated healthcare real estate exposure.